IP Group

Lumai is a developer of optical computing networks that integrates photonics and machine learning to create fully optical computing solutions. The company aims to revolutionize computing by providing faster, smarter, and more sustainable technology compared to traditional electronic systems. By leveraging optical computing, Lumai significantly reduces energy consumption while enhancing processing speeds and scalability. This innovation allows both consumers and clients to access next-generation artificial intelligence capabilities, positioning Lumai at the forefront of advancements in the computing landscape.

DiffBlue Limited is a developer of artificial intelligence software focused on automating coding tasks, particularly in Java development. Established in 2016 and based in Oxford, United Kingdom, the company specializes in automated testing software that generates unit tests autonomously. DiffBlue's technology leverages reinforcement learning to create fully formed tests that compile and run successfully, addressing one of the most challenging aspects of software development—writing unit tests. In addition to test generation, the company's software aids in bug fixing, refactoring code, translating programming languages, and enhancing security by identifying and rectifying vulnerabilities. DiffBlue's solutions not only save developers time but also provide valuable insights into test coverage, code testability, complexity, dependencies, and code churn, ultimately transforming the software writing process.

Alimetry is a health technology startup located in Auckland, New Zealand, focused on creating innovative solutions for diagnosing gastrointestinal (GI) disorders. The company has developed a symptom-tracking and real-time gastric mapping monitoring device that investigates gastric function. This device senses the underlying motility of the stomach to identify the causes of common symptoms such as abdominal pain, indigestion, nausea, and vomiting. By providing insights into GI health, Alimetry aims to enhance patient care and improve the management of gastrointestinal disorders.

Alesi Surgical Ltd. is a company based in Cardiff, United Kingdom, specializing in the development and commercialization of laparoscopic surgical smoke handling systems. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, Alesi Surgical focuses on creating products that enhance the safety, efficiency, and outcomes of surgical procedures. Its innovative tools are portable and suitable for both laparoscopic and robot-assisted surgeries, utilizing electrostatic precipitation technology to eliminate surgical smoke and maintain a clear visual field during operations. The company distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia, leveraging its access to experienced surgeons and surgical trainers to identify challenges in surgical procedures and design effective solutions.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Oxford Quantum Circuits is a developer of advanced quantum computing technology that aims to address significant global challenges, such as climate change and drug discovery. The company focuses on creating unique superconducting circuits essential for quantum computation, ensuring high-quality qubit control and maintaining operational efficiency. Their quantum computers are fully integrated units, comprising the necessary control systems, hardware, and software, which enable customers to enhance their operations, innovate new methodologies, and tackle pressing issues. Through its pioneering technology, Oxford Quantum Circuits contributes to groundbreaking advancements that hold the potential for transformative impacts across various industries.

Crescendo Biologics Limited is a clinical-stage biotechnology company based in Cambridge, United Kingdom, specializing in the development of innovative therapies for oncology and dermatology. The company focuses on creating multi-specific immune-oncology modulators and Humabody Drug Conjugates using its proprietary transgenic mouse platform. This technology allows for the in vivo maturation of human VH domains, optimizing their affinity and biophysical properties for therapeutic use. Crescendo Biologics aims to address critical challenges in generating high-affinity, soluble human VH antibody fragments, which are recognized for their potential as effective therapeutics. By leveraging its advanced platforms, the company is engaged in the product development of in-house targets as well as collaborations with other organizations to enhance the efficacy of cancer treatments. Founded in 2007 and originally known as Translocus Limited, Crescendo Biologics has established itself as a leader in the field of next-generation antibody therapeutics.

OxCCU is a technology developer focused on facilitating a circular economy for fuels, chemicals, and plastics. It achieves this by innovating renewable energy solutions that convert atmospheric carbon dioxide into valuable products such as fuels, chemicals, and biodegradable plastics using hydrogen derived from water and renewable electricity.

AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) and channel coding solutions for wireless communications. Founded in 2016, the company develops advanced error correction technologies, including Polar and Turbo Decoders, as well as LDPC encoding and decoding chains, which are compliant with 3GPP standards. These technologies are designed to enhance the performance of next-generation wireless communication systems, addressing challenges such as noise, interference, and poor signal quality. By offering innovative solutions that improve the efficiency and reliability of communication networks, AccelerComm aims to support the evolution of mobile technology beyond 3G and 4G standards.

Deep Render Ltd. is a London-based AI startup that specializes in developing advanced media compression algorithms. Originating as a spin-out from the Department of Computing at Imperial College London, the company focuses on leveraging proprietary and patented technology to enhance media compression through deep learning techniques. Its innovative approach includes the application of density estimation, unsupervised learning, and quantum methods, resulting in state-of-the-art Biological Image Compression that achieves a minimum of 50% efficiency improvement over existing standards. Additionally, Deep Render is recognized for creating the first AI codec capable of real-time video playback, which allows for enhanced market opportunities and significant cost reductions for users.

Intrinsic Semiconductor Technologies specializes in the development of silicon-oxide based resistive random-access memory (RRAM) technologies. The company focuses on creating non-volatile memory solutions that are fully air stable and compatible with complementary metal-oxide-semiconductor (CMOS) processes. Intrinsic's innovative technology can be adapted for various applications, including multilevel memory, hardware acceleration for machine learning, and neuromorphic devices. By utilizing low-power, cost-effective semiconductors and gallium nitride materials, the company enables the integration of its devices into standard CMOS architectures, even at advanced process nodes. This capability allows clients to achieve higher performance under demanding conditions, such as elevated temperatures and frequencies.

Quantum Motion Technologies specializes in developing a universal quantum computer utilizing silicon-based architectures compatible with CMOS processes. The company focuses on creating scalable quantum computing technology that addresses key challenges such as fault tolerance and qubit redundancy. By leveraging complementary metal-oxide semiconductor technology, Quantum Motion aims to enhance the density of qubits, enabling the construction of larger and more efficient quantum systems. This advancement is intended to facilitate significant improvements in quantum computing applications, assisting clients in the quantum technology sector to minimize errors and overcome critical challenges in quantum information and technology.

AudioScenic Limited, founded in 2017 and headquartered in Southampton, United Kingdom, specializes in developing innovative 3D audio technology that enhances the listening experience across various industries including cinema, gaming, production, automotive, and public displays. The company utilizes small arrays of speakers combined with advanced head-tracking technologies to create controlled and independent sound beams directed to each ear, effectively simulating a virtual headphone experience without the need for traditional headphones or extensive speaker setups. This approach delivers a more authentic and immersive audio experience, allowing sounds to be perceived in three-dimensional space with remarkable clarity. AudioScenic’s technology eliminates the limitations of conventional loudspeaker systems by providing optimized sound delivery that adapitates to the listener's position. Their proprietary Virtua 3D Engine enables wide-ranging applications and cost-effective implementations, offering detailed acoustic design support to partners and customers in various market segments.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

DiffBlue Limited is a developer of artificial intelligence software focused on automating coding tasks, particularly in Java development. Established in 2016 and based in Oxford, United Kingdom, the company specializes in automated testing software that generates unit tests autonomously. DiffBlue's technology leverages reinforcement learning to create fully formed tests that compile and run successfully, addressing one of the most challenging aspects of software development—writing unit tests. In addition to test generation, the company's software aids in bug fixing, refactoring code, translating programming languages, and enhancing security by identifying and rectifying vulnerabilities. DiffBlue's solutions not only save developers time but also provide valuable insights into test coverage, code testability, complexity, dependencies, and code churn, ultimately transforming the software writing process.

Kale United AB, founded in 2018 and headquartered in Stockholm, Sweden, specializes in providing advisory services to plant-based member companies. These services encompass marketing, public relations, sales and distribution, financing, community engagement, accounting, and human resources. The company focuses on supporting vegan startups and aims to foster growth within the plant-based food sector across the Nordic region.

Innervace is a regenerative therapy company established in 2018 and based in Philadelphia, Pennsylvania. It focuses on developing and commercializing implantable tissue-engineered brain pathways aimed at addressing neurodegenerative disorders. The company's primary innovation is its tissue-engineered nigrostriatal pathway, which is designed to replicate the lost nigrostriatal pathway in patients suffering from Parkinson's disease. This advanced technology offers a solution that reconstructs brain pathways rather than merely alleviating symptoms temporarily, thus providing a more effective treatment option for individuals with such conditions.

AMSL Aero is a company focused on developing electric vertical take-off and landing aircraft, specifically its flagship model, Vertiia. This innovative aircraft is designed to cruise at speeds of 300 km/h and has a range of 250 km on electric battery power alone. AMSL Aero aims to revolutionize transportation across various sectors, including aeromedical, emergency services, and passenger services. By providing a mode of transport that enables passengers to bypass traffic congestion and travel swiftly from locations with landing pads, AMSL Aero is committed to enhancing human mobility with a safe, fast, and environmentally friendly solution.

Somalytics is a Seattle-based company that specializes in the development and commercialization of innovative miniature sensors for applications such as eye tracking, human-machine interfaces, wearables, and industrial safety. Founded in 2021, the company has created the world's first paper-composite capacitive sensor, which is ultra-thin, energy-efficient, and potentially disposable. These carbon nanotube-based sensors enhance sensitivity and aim to replace traditional cameras and sensors in various devices, thereby improving the overall human experience through advanced technology.

Nexeon Limited is a battery materials and licensing company specializing in the development of silicon anodes for lithium-ion batteries. Founded in 2006 and headquartered in Abingdon, United Kingdom, with an additional office in Yokohama, Japan, Nexeon focuses on providing innovative silicon-based anode materials that enhance energy density and battery capacity. Its technology is applicable across various industries, including consumer electronics, electric vehicles, sustainable energy, aerospace, medical, and defense. By enabling lighter and more efficient batteries, Nexeon's solutions contribute to improved performance and longer lifetimes between charges, supporting the transition to sustainable energy and the achievement of net-zero goals. The company boasts a multidisciplinary technical team with diverse expertise, dedicated to advancing battery technology for a range of consumer and commercial markets.

Hysata is focused on advancing hydrogen electrolyzer technology to facilitate the production of green hydrogen, aiming to significantly reduce costs to below $2 per kilogram. This innovative approach is rooted in research from the University of Wollongong's ARC Centre of Excellence for Electromaterials Science, led by Professor Gerry Swiegers. The company’s electrolyzers operate by using electricity to separate water into hydrogen and oxygen, thereby supporting the transition from fossil fuels to sustainable energy sources. Hysata's initiatives are designed to play a crucial role in helping businesses achieve net-zero emissions and accelerate the global move towards environmentally friendly energy solutions.

Oxford Science Enterprises is a venture firm based in Oxford, United Kingdom, established in 2015 in partnership with the University of Oxford. The firm focuses on building and investing in companies that develop fundamental technologies aimed at addressing significant global challenges. Its investment areas include life sciences, healthcare, artificial intelligence, software, and deep tech, targeting issues such as nuclear fusion, quantum computing, and the development of treatments for infectious diseases. By leveraging its extensive experience and a robust network of investors, entrepreneurs, and sector experts, Oxford Science Enterprises aims to foster a world-class technology ecosystem and support the growth of innovative science-based businesses.

Abliva AB is a Swedish pharmaceutical company focused on the research and development of treatments for primary mitochondrial diseases, which are rare and severe conditions caused by dysfunctional mitochondria. The company's pipeline includes KL1333, currently in phase I clinical trials, and NV354, an energy replacement therapy that is preparing for clinical trials. KL1333 is noted for its role as a regulator of NAD+ and NADH, and has received orphan drug designation in both Europe and the United States. Additionally, Abliva is developing NeuroSTAT for the treatment of traumatic brain injury. Established in 2000 and headquartered in Lund, Sweden, Abliva has formed collaborations with various institutions, enhancing its research capabilities and clinical development efforts.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.

SLAMcore Limited is a London-based company specializing in advanced simultaneous localization and mapping (SLAM) solutions tailored for augmented reality, robotics, and autonomous vehicles. Founded in 2016, SLAMcore develops software that enables devices with outward-looking sensors to accurately localize, navigate, and comprehend unfamiliar environments. Their offerings include Visual SLAM, sensor fusion techniques, and Event Camera SLAM, which facilitates incremental tracking and mapping from event camera data. By leveraging spatial artificial intelligence, the company fuses information from various sensors to create a cohesive understanding of surroundings, optimizing performance while reducing energy consumption. Through its software development kit (SDK), SLAMcore supports rapid prototyping and customization for commercial applications in industrial and consumer robotics, positioning its technology as a critical component in advancing the integration of robotic solutions into daily life.

GripAble Ltd. is a London-based company founded in 2017 that specializes in the development of digital therapy devices aimed at improving rehabilitation for individuals with movement impairments. The company’s flagship product, the GripAble Digital Handgrip, is a sensitive, portable device that wirelessly connects to a mobile application. This app allows users to engage in interactive therapy games designed to facilitate the assessment and training of hand and arm functions. GripAble's solutions target patients suffering from conditions such as stroke, arthritis, cerebral palsy, and trauma, addressing the challenges faced by over 500 million people globally who experience impaired arm mobility. By combining hardware with gamified therapy, GripAble enhances patient engagement and enables effective self-training both in clinical settings and at home.

Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. By targeting the Kaiser-Meyer-Olkin (KMO) enzyme, the company aims to regulate systemic inflammation and tackle the underlying pathology of various medical conditions. Kynos Therapeutics is dedicated to providing innovative therapies that represent a new generation of potent KMO inhibitors, offering potential solutions in areas where current treatment options are limited.

Aptatek Biosciences Inc specializes in the development of portable medical devices for the management of Phenylketonuria (PKU), a genetic disorder that affects metabolism. Based in Princeton, New Jersey, the company utilizes advanced sensor technology to provide real-time monitoring of phenylalanine levels in patients. Its innovative devices enable users to conduct blood tests on-the-go, facilitating immediate dietary adjustments to maintain phenylalanine levels within clinical target ranges. By leveraging DNA aptamer sequences, Aptatek can detect a variety of small-molecule biomarkers and other health indicators, enhancing the diagnosis and management of PKU and other inborn diseases. This technology aims to improve patient compliance and overall quality of life while streamlining the traditional laboratory analysis process.

Vytal is a company that specializes in software-enabled reusable packaging solutions aimed at reducing single-use packaging waste in the food and beverage sector. It provides a comprehensive reusable container system along with container management software, which supports sustainable takeaway and delivery services. Vytal caters to a diverse clientele, including restaurants, supermarkets, caterers, canteens, and event organizers, offering them high-quality reusable packaging options at a pay-per-use cost that is more economical than disposable alternatives. Consumers can conveniently borrow containers for free and return them at various locations or through delivery services, thus promoting a circular economy and facilitating efforts to minimize plastic waste.

Alimetry is a health technology startup located in Auckland, New Zealand, focused on creating innovative solutions for diagnosing gastrointestinal (GI) disorders. The company has developed a symptom-tracking and real-time gastric mapping monitoring device that investigates gastric function. This device senses the underlying motility of the stomach to identify the causes of common symptoms such as abdominal pain, indigestion, nausea, and vomiting. By providing insights into GI health, Alimetry aims to enhance patient care and improve the management of gastrointestinal disorders.

Helio Display Materials is a developer of innovative perovskite-based materials aimed at enhancing display technology. The company focuses on creating materials that enable brighter and more colorful displays while significantly reducing power consumption. By leveraging metal halide perovskites, which can be synthesized using low-temperature processes and earth-abundant precursor materials, Helio aims to produce vibrant and efficient light-emitting technologies for televisions and displays. The company emphasizes collaboration with scientific and industry experts to expedite research and development, ensuring a strong scientific foundation for its intellectual property. Helio's mission is to improve display performance and efficiency, ultimately providing a superior visual experience.

Barocal is a developer of innovative cooling technology focused on meeting low-carbon refrigeration needs. The company utilizes materials that experience significant thermal changes when pressure is applied or removed, leading to enhanced energy efficiency and a zero greenhouse warming impact. This technology is particularly beneficial for commercial food and drink refrigeration, allowing clients to effectively lower indirect greenhouse gas emissions. By prioritizing sustainability, Barocal aims to contribute to a more environmentally friendly approach to refrigeration.

First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.

Bramble Energy Ltd. is a London-based company that designs, develops, and manufactures printed circuit board fuel cells (PCBFC), specifically proton exchange membrane fuel cells (PEMFCs). Founded in 2016, the company utilizes innovative PCB technology to create high-performance and cost-effective fuel cell stacks, including variants of 20 W, 500 W, and 5 kW, along with custom-designed options. By leveraging the capabilities of the global high-volume PCB industry, Bramble Energy stands out as the first fuel cell manufacturer with the capacity to produce gigawatts of fuel cell hardware, a feat that has eluded the battery industry for years. The company's products serve various sectors, including stationary, portable, and automotive applications, offering businesses and energy industry players access to efficient solutions that help reduce energy consumption and lower carbon emissions.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

DiffBlue Limited is a developer of artificial intelligence software focused on automating coding tasks, particularly in Java development. Established in 2016 and based in Oxford, United Kingdom, the company specializes in automated testing software that generates unit tests autonomously. DiffBlue's technology leverages reinforcement learning to create fully formed tests that compile and run successfully, addressing one of the most challenging aspects of software development—writing unit tests. In addition to test generation, the company's software aids in bug fixing, refactoring code, translating programming languages, and enhancing security by identifying and rectifying vulnerabilities. DiffBlue's solutions not only save developers time but also provide valuable insights into test coverage, code testability, complexity, dependencies, and code churn, ultimately transforming the software writing process.

Lumai is a developer of optical computing networks that integrates photonics and machine learning to create fully optical computing solutions. The company aims to revolutionize computing by providing faster, smarter, and more sustainable technology compared to traditional electronic systems. By leveraging optical computing, Lumai significantly reduces energy consumption while enhancing processing speeds and scalability. This innovation allows both consumers and clients to access next-generation artificial intelligence capabilities, positioning Lumai at the forefront of advancements in the computing landscape.

Canopus Networks Pty Ltd is an Australian company founded in 2018, specializing in software-defined networking and artificial intelligence technologies. The company focuses on providing solutions for internet service providers to effectively manage and isolate streaming video and gaming traffic, ensuring a consistent user experience during network congestion. Canopus develops a platform that offers encryption-proof network observability, enabling high-speed analysis of network flows. This platform is essential for telecommunications operators who need to monitor application and network performance amidst increasing data rates and encryption challenges. Canopus serves various sectors, including fixed operators, gaming, 5G mobile operators, live video streaming, business applications, security, and government entities.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Ieso Digital Health Ltd. is a United Kingdom-based company specializing in online evidence-based mental health therapy. Founded in 2000 and formerly known as PsychologyOnline.co.uk Limited, Ieso provides a platform for one-to-one therapy sessions, allowing patients to engage with accredited therapists in a virtual environment tailored to their schedules. The company addresses a variety of mental health conditions, including anxiety, depression, eating disorders, and relationship issues, as well as chronic physical health problems and cognitive impairments. Utilizing cognitive behavioral therapy (CBT), Ieso employs proprietary technology enhanced by natural language processing and artificial intelligence to facilitate real-time monitoring and improve therapeutic outcomes. Its services cater to a diverse clientele, including health providers, private individuals, and businesses, aiming to transform the landscape of mental healthcare through scalable digital products and therapeutics.

Ieso Digital Health Ltd. is a United Kingdom-based company specializing in online evidence-based mental health therapy. Founded in 2000 and formerly known as PsychologyOnline.co.uk Limited, Ieso provides a platform for one-to-one therapy sessions, allowing patients to engage with accredited therapists in a virtual environment tailored to their schedules. The company addresses a variety of mental health conditions, including anxiety, depression, eating disorders, and relationship issues, as well as chronic physical health problems and cognitive impairments. Utilizing cognitive behavioral therapy (CBT), Ieso employs proprietary technology enhanced by natural language processing and artificial intelligence to facilitate real-time monitoring and improve therapeutic outcomes. Its services cater to a diverse clientele, including health providers, private individuals, and businesses, aiming to transform the landscape of mental healthcare through scalable digital products and therapeutics.

Ultraleap Limited is a leading developer of mid-air haptic control systems and 3D hand tracking technology. Formerly known as Ultrahaptics, the company specializes in creating solutions that utilize ultrasound to generate tactile sensations, enabling users to feel three-dimensional shapes and textures without physical contact. Its flagship products include the Leap Motion Controller, which captures hand movements, and the VR Developer Mount, designed for enhancing virtual reality experiences on various headsets. The company's innovative technology is applicable across multiple industries such as extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment. Established in 2013 and headquartered in Bristol, United Kingdom, Ultraleap also has a subsidiary in Silicon Valley, United States.

Teya is a comprehensive solution tailored for small and growing businesses, offering a suite of services that facilitate efficient management and growth. The company specializes in payment processing, providing fast and secure transaction capabilities, along with cloud-native business management software. Teya's offerings include issuer payment processing and cash advance services, which assist merchants in enhancing their operations. With a commitment to supporting over 300,000 business owners, Teya enables them to effectively manage their businesses and fosters a positive experience in their entrepreneurial journey.

Hinge Health, established in 2015, specializes in digital healthcare solutions for musculoskeletal disorders, primarily targeting back and joint pains. The company offers wearable sensor technology, tablet computers, and support services, guiding users through physical therapy and weight loss activities. Their solutions are designed to be accessible and convenient, serving both individuals and businesses. Hinge Health's headquarters are in San Francisco, with additional offices in Chicago, Minneapolis, Portland, and London.

Inosi Therapeutics is a biotechnology company focused on developing innovative therapies to treat fibrosis, a condition characterized by tissue damage and scarring that can result in the loss of organ function. The company is pioneering a therapeutic approach that utilizes IRAP inhibitors, which can be tested independently or in conjunction with existing standard treatments. This unique mechanism of action aims to enhance the treatment of organ damage related to diabetes-induced kidney disease and cardiovascular disease. By addressing the underlying causes of fibrosis, Inosi Therapeutics aims to provide healthcare providers with effective solutions for managing chronic diseases associated with significant tissue damage.

Quantum Dice is an award-winning spin-out from the University of Oxford specializing in quantum technology. The company develops quantum random number generators (QRNGs) that produce unbiased, true random numbers essential for secure communication technologies. These generators are designed to enhance security by utilizing quantum processes to ensure that the random numbers generated are cryptographically secure and resistant to external influences. Quantum Dice's innovative approach offers improved encryption systems that are vital for a secure connected future across various commercial applications.

Monolith AI Limited is a software company based in London, United Kingdom, founded in 2016. The company specializes in developing algorithms that integrate engineering simulations with machine learning techniques to enhance the engineering design process. By leveraging existing simulation and test data, Monolith AI enables engineers to predict the behavior of new products more accurately, thereby optimizing research and development efforts. This approach reduces the need for extensive simulations, tests, and prototypes, allowing companies to accelerate product development and improve overall product quality. Monolith AI was previously known as UQuant Limited until it rebranded in June 2018.

Arkivum Limited, established in 2011 and based in Chippenham, UK, specializes in long-term data management and digital preservation solutions. Serving data-intensive and regulated industries such as healthcare, life sciences, and finance, Arkivum provides a suite of products including Arkivum/100, Arkivum/1+1, Arkivum/OnSite, Perpetua, Archive Builder Toolkit, and QStar Network Migrator. These solutions ensure data is securely stored, accessible, and usable for extended periods, with a focus on data integrity and compliance. Arkivum's services are delivered through a network of reseller and OEM channel partners.

Alesi Surgical Ltd. is a company based in Cardiff, United Kingdom, specializing in the development and commercialization of laparoscopic surgical smoke handling systems. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, Alesi Surgical focuses on creating products that enhance the safety, efficiency, and outcomes of surgical procedures. Its innovative tools are portable and suitable for both laparoscopic and robot-assisted surgeries, utilizing electrostatic precipitation technology to eliminate surgical smoke and maintain a clear visual field during operations. The company distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia, leveraging its access to experienced surgeons and surgical trainers to identify challenges in surgical procedures and design effective solutions.

MOBILion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, focused on developing advanced analytical instrumentation for the detection and analysis of clinically relevant molecules. The company specializes in structures for lossless ion manipulation (SLIM), which facilitate ion mobility separations with high sensitivity and resolution. This technology allows researchers to identify and analyze challenging biomolecules, including proteins, peptides, metabolites, glycans, and lipids, that traditional instruments often fail to detect. By improving the accuracy of diagnostic tests and enabling earlier disease detection, MOBILion's innovations support the development of better therapeutics and enhance the ability to monitor and treat medical conditions effectively. Since its incorporation in 2015, MOBILion Systems has aimed to transform disease prediction, diagnosis, and treatment through its state-of-the-art technology.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Intrinsic Semiconductor Technologies specializes in the development of silicon-oxide based resistive random-access memory (RRAM) technologies. The company focuses on creating non-volatile memory solutions that are fully air stable and compatible with complementary metal-oxide-semiconductor (CMOS) processes. Intrinsic's innovative technology can be adapted for various applications, including multilevel memory, hardware acceleration for machine learning, and neuromorphic devices. By utilizing low-power, cost-effective semiconductors and gallium nitride materials, the company enables the integration of its devices into standard CMOS architectures, even at advanced process nodes. This capability allows clients to achieve higher performance under demanding conditions, such as elevated temperatures and frequencies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Oxular Limited is a clinical-stage company based in Oxford, United Kingdom, focused on developing innovative retinal treatments aimed at addressing various retinal diseases. Founded in 2014, the company specializes in tissue-specific drug delivery technologies designed to enhance the effectiveness of treatments for conditions such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema. By targeting specific areas within the eye, Oxular aims to improve patient outcomes, reduce side effects, and decrease the frequency of treatments required. The company is committed to transforming the landscape of retinal therapeutics and providing life-changing solutions for patients facing unmet medical needs.

C-Capture Limited is a company based in Leeds, United Kingdom, founded in 2008, specializing in the development and design of solvent systems for the removal of carbon dioxide (CO2) from gas streams. The firm employs a bottom-up approach to create proprietary carbon capture solvent technology that targets the economic and non-toxic extraction of CO2 from emission sources. This technology is particularly aimed at post-combustion capture processes in power generation and hard-to-abate industries, addressing the significant role of CO2 as a greenhouse gas and its contribution to global warming. By providing absorbents and solvents, C-Capture supports the implementation of carbon capture and storage (CCS), promoting environmentally sustainable electricity generation.

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovating the drug development process through an asset-centric research and development model. The company manages a diverse portfolio of therapeutics across several therapeutic areas, including SerpinPC for Hemophilia A and B, LB101 for solid tumors, ORX750 for Narcolepsy Type 1 and other sleep disorders, and MGX292 for pulmonary arterial hypertension. Each therapeutic program is developed by a dedicated subsidiary, leveraging a centralized infrastructure and experienced management team to ensure efficient advancement of its pipeline assets.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Oxa is a developer of autonomous vehicle software that focuses on creating AI-based platforms for the operation and scaling of fleets of autonomous vehicles. The company's technology combines laser vision and radar for effective localization, allowing autonomous systems to understand their surroundings and navigate safely in complex environments. Oxa's software is designed to operate with low compute power requirements, making it accessible for various business applications. By providing solutions that enhance vehicle positioning and movement prediction, Oxa enables clients to implement and accelerate the deployment of autonomous vehicles in a range of settings.

8Power Limited specializes in the manufacture of autonomous sensor systems tailored for various sectors, including automotive, transportation, civil engineering, industrial equipment, and utility infrastructure. The company has developed a wireless sensor technology that provides real-time condition monitoring data and analytics, allowing industrial clients to continuously monitor the performance of their assets. This technology is particularly effective for managing thousands of remote assets, such as pumps, motors, and gearboxes, facilitating machine condition monitoring at a lower cost. 8Power's solutions are designed for easy installation and application across industries such as water and waste treatment, manufacturing, and oil and gas, enhancing operational efficiency and asset management.

Econic Technologies Ltd. is a chemical technology company based in Macclesfield, United Kingdom, specializing in the development of innovative processes to convert carbon dioxide and epoxides into valuable polymers and polyurethanes. Founded in 2011, the company leverages catalyst chemistry to transform waste CO2 into commercially viable products, thereby reducing dependence on fossil fuels and providing environmental benefits. Econic's product offerings include polycarbonates and polycarbonate polyols, which are utilized in various applications such as mattresses, insulation, footwear, packaging, and construction materials. Additionally, the company produces glues and coatings for industrial uses. With patented catalyst technologies and a skilled team of scientists and engineers, Econic Technologies operates from a state-of-the-art facility at Alderley Park, focusing on turning scientific advancements into practical solutions for the plastics industry while addressing environmental challenges.

AudioScenic Limited, founded in 2017 and headquartered in Southampton, United Kingdom, specializes in developing innovative 3D audio technology that enhances the listening experience across various industries including cinema, gaming, production, automotive, and public displays. The company utilizes small arrays of speakers combined with advanced head-tracking technologies to create controlled and independent sound beams directed to each ear, effectively simulating a virtual headphone experience without the need for traditional headphones or extensive speaker setups. This approach delivers a more authentic and immersive audio experience, allowing sounds to be perceived in three-dimensional space with remarkable clarity. AudioScenic’s technology eliminates the limitations of conventional loudspeaker systems by providing optimized sound delivery that adapitates to the listener's position. Their proprietary Virtua 3D Engine enables wide-ranging applications and cost-effective implementations, offering detailed acoustic design support to partners and customers in various market segments.

Alimetry is a health technology startup located in Auckland, New Zealand, focused on creating innovative solutions for diagnosing gastrointestinal (GI) disorders. The company has developed a symptom-tracking and real-time gastric mapping monitoring device that investigates gastric function. This device senses the underlying motility of the stomach to identify the causes of common symptoms such as abdominal pain, indigestion, nausea, and vomiting. By providing insights into GI health, Alimetry aims to enhance patient care and improve the management of gastrointestinal disorders.

Augmented Bionics is focused on creating a non-surgical alternative to cochlear implants for individuals with severe to profound hearing loss. The company leverages Transcranial Magnetic Stimulation (TMS), a safe and FDA-approved neuromodulation technology, to develop its innovative device. Unlike traditional hearing aids, which are ineffective for this demographic, Augmented Bionics' solution offers the convenience of a wearable device similar to headphones while providing the functionality of a cochlear implant. This approach aims to reduce barriers to access, such as the risks, high costs, and specialist requirements associated with surgical implants. By addressing the needs of the over 70 million people affected by profound hearing loss, Augmented Bionics seeks to transform the treatment landscape and enhance the quality of life for its users.

AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) and channel coding solutions for wireless communications. Founded in 2016, the company develops advanced error correction technologies, including Polar and Turbo Decoders, as well as LDPC encoding and decoding chains, which are compliant with 3GPP standards. These technologies are designed to enhance the performance of next-generation wireless communication systems, addressing challenges such as noise, interference, and poor signal quality. By offering innovative solutions that improve the efficiency and reliability of communication networks, AccelerComm aims to support the evolution of mobile technology beyond 3G and 4G standards.

MOBILion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, focused on developing advanced analytical instrumentation for the detection and analysis of clinically relevant molecules. The company specializes in structures for lossless ion manipulation (SLIM), which facilitate ion mobility separations with high sensitivity and resolution. This technology allows researchers to identify and analyze challenging biomolecules, including proteins, peptides, metabolites, glycans, and lipids, that traditional instruments often fail to detect. By improving the accuracy of diagnostic tests and enabling earlier disease detection, MOBILion's innovations support the development of better therapeutics and enhance the ability to monitor and treat medical conditions effectively. Since its incorporation in 2015, MOBILion Systems has aimed to transform disease prediction, diagnosis, and treatment through its state-of-the-art technology.

Bramble Energy Ltd. is a London-based company that designs, develops, and manufactures printed circuit board fuel cells (PCBFC), specifically proton exchange membrane fuel cells (PEMFCs). Founded in 2016, the company utilizes innovative PCB technology to create high-performance and cost-effective fuel cell stacks, including variants of 20 W, 500 W, and 5 kW, along with custom-designed options. By leveraging the capabilities of the global high-volume PCB industry, Bramble Energy stands out as the first fuel cell manufacturer with the capacity to produce gigawatts of fuel cell hardware, a feat that has eluded the battery industry for years. The company's products serve various sectors, including stationary, portable, and automotive applications, offering businesses and energy industry players access to efficient solutions that help reduce energy consumption and lower carbon emissions.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Oxford Ionics is a quantum computing startup focused on developing high-performance quantum computers through the use of trapped-ion technology. The company combines advanced qubit designs with a noiseless electronic control system, allowing for accurate and reliable manipulation of qubits. This technology enables the parallel control of interconnected qubit registers, ensuring performance is not compromised. By employing standard semiconductor fabrication methods, Oxford Ionics aims to create scalable quantum chips that enhance computational capabilities for complex problem-solving. The company's innovations position it to significantly advance the quantum computing market, providing clients with dependable solutions for high-performance applications.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

IBEX Innovations Limited, established in 2010 and based in Sedgefield, UK, specializes in developing and commercializing advanced X-ray detector technology. The company's flagship product, IBEX multi absorption plate (MAP) technology, enhances standard X-ray detectors to generate high-sensitivity materials information while retaining key characteristics such as speed, signal-to-noise ratio, spatial resolution, and imaging area. IBEX Innovations serves diverse applications including bone mineral density measurement in medical diagnostics, electronics inspection, food safety, and security screening. The company collaborates with academic institutions like Durham University for technology development and NHS trusts for medical application validation. Backed by venture capital funding from Northstar Ventures, IP Group, Nordson Incorporated, Innovate UK, and the European Commission, IBEX Innovations aims to revolutionize X-ray imaging across various industries.

Quantum Motion Technologies specializes in developing a universal quantum computer utilizing silicon-based architectures compatible with CMOS processes. The company focuses on creating scalable quantum computing technology that addresses key challenges such as fault tolerance and qubit redundancy. By leveraging complementary metal-oxide semiconductor technology, Quantum Motion aims to enhance the density of qubits, enabling the construction of larger and more efficient quantum systems. This advancement is intended to facilitate significant improvements in quantum computing applications, assisting clients in the quantum technology sector to minimize errors and overcome critical challenges in quantum information and technology.

RFC Power Ltd is a London-based company established in 2017 that specializes in the development of innovative hybrid flow battery systems designed for renewable energy storage. The company focuses on creating low-cost redox flow battery chemistry, utilizing non-toxic and abundant materials. By integrating concepts from fuel cells, RFC Power aims to optimize its battery architecture, employing a unique hydrogen manganese chemistry in a hybrid gas-liquid configuration. This approach enables the company to offer a reliable energy storage solution with minimal capacity loss, ensuring that stored renewable energy can be accessed safely and efficiently when needed.

Instrumems Inc. is a technology company based in Los Altos, California, specializing in the development of innovative nano-wire sensors. Founded in 2016, the company focuses on creating a versatile sensing platform capable of measuring temperature, flow velocity, and humidity. Instrumems' sensors are designed to be faster, more cost-effective, and smaller in size compared to traditional measurement techniques. Their technology is increasingly relevant in various sectors, including aerospace, automotive, and environmental monitoring, facilitating applications such as real-time weather tracking and distributed climate monitoring. The company's multi-sensor solutions leverage high-resolution and high-frequency measurement capabilities, providing clients with industry-leading response times, accuracy, and ultra-low power consumption.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

MOBILion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, focused on developing advanced analytical instrumentation for the detection and analysis of clinically relevant molecules. The company specializes in structures for lossless ion manipulation (SLIM), which facilitate ion mobility separations with high sensitivity and resolution. This technology allows researchers to identify and analyze challenging biomolecules, including proteins, peptides, metabolites, glycans, and lipids, that traditional instruments often fail to detect. By improving the accuracy of diagnostic tests and enabling earlier disease detection, MOBILion's innovations support the development of better therapeutics and enhance the ability to monitor and treat medical conditions effectively. Since its incorporation in 2015, MOBILion Systems has aimed to transform disease prediction, diagnosis, and treatment through its state-of-the-art technology.

Kira Biotech Pty Ltd is an Australian biotechnology company founded in 2017 and headquartered in Brisbane. The company focuses on developing innovative immunomodulatory compounds aimed at treating various immune system disorders, including rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes. Its lead candidate, KB312, is a first-in-class, selective monoclonal antibody designed to target activated immune cells, thereby promoting immune tolerance and restoring homeostasis. The company is advancing KB312 through preclinical development and phase 1 clinical trials, supported by a team of drug development experts, including notable rheumatologist and immunologist Dr. Dan Baker. Kira Biotech has also successfully secured venture capital funding to support its research and development activities.

Inflowmatix Limited, founded in 2015 and based in London, specializes in developing electronic systems for water utilities that enhance water flow and system health analytics. As a spin-out from Imperial College London's InfraSense Labs, the company leverages cross-disciplinary expertise in sensing, modeling, and optimization to address challenges faced by water supply networks, including aging infrastructure and increasing demand. Inflowmatix's technology focuses on continuously monitoring fluid dynamics and capturing high-frequency pressure data, which allows operators to gain valuable insights and optimize network performance. This capability not only improves the management of leakage and demand but also enhances energy efficiency and extends the lifespan of critical assets. By providing advanced analytics and operational strategies, Inflowmatix helps water companies navigate regulatory pressures and deliver high-quality services while managing limited resources effectively.

CareAlign is a developer of a real-time data system that enhances the management and coordination of clinical care for clinicians. The company offers an intuitive, patient-centric task management tool that allows healthcare professionals to assign tasks, set deadlines, and categorize them based on urgency. By aggregating data from multiple sources, CareAlign provides a comprehensive and clinically intuitive display of patients' clinical status, facilitating better understanding and decision-making in patient care. This system aims to streamline workflows and improve communication among clinicians, ultimately enhancing the quality of care delivered to patients.

Growave is an Agtech startup company offering herbicide free weed management.

WaveOptics, Ltd. is a designer and manufacturer of advanced augmented reality display technology, specializing in diffractive waveguides for wearable devices. Founded in 2014 and headquartered in Abingdon-on-Thames, United Kingdom, the company focuses on providing key optical components for augmented reality applications. WaveOptics employs patented technology that utilizes waveguide holography and photonic crystals to create lightweight, high-performance displays. Their innovative designs feature a high field of view and full RGB color, allowing for an enriched user experience without the bulk typically associated with traditional augmented reality systems. The company has established strategic partnerships with leading firms such as Compal, Wistron, and Plessey to enhance its product offerings and market reach.

SAM Labs Limited is an education technology company based in London, United Kingdom, established in 2014. It specializes in providing educators with resources that enhance teaching and learning experiences, particularly in the areas of coding and computational skills. The company offers a range of products including wireless electronic blocks, such as buttons, sensors, motors, and sliders, which can be connected via an intuitive software application called SAM Space. This platform allows students to visualize and code the blocks, enabling them to create interactive projects and engage in hands-on learning. SAM Labs also supplies curriculum-based lesson plans and in-classroom support to facilitate STEAM education, making coding accessible and fun. Its course kits and electronic products are available for purchase online, helping educators deliver comprehensive and engaging lessons across various subjects.

Exyn Technologies, Inc. is a Philadelphia-based company that specializes in the development of autonomous aerial robots designed for complex commercial environments. Founded in 2014 as a spin-off from the GRASP Laboratory at the University of Pennsylvania, Exyn leverages over a decade of research to create drone platforms capable of pilot-less operation without reliance on GPS. Its flagship software, exynAI, manages the control and communication of these multi-sensory rotorcraft, enabling them to perform tasks such as underground inspections, inventory management, and construction documentation. The company's innovative approach combines multiple redundant sensors with advanced mapping and obstacle avoidance technologies, resulting in highly robust and differentiated aerial robots that facilitate data acquisition in challenging settings.

Azuri Technologies Ltd. specializes in the development, manufacturing, and installation of solar power products aimed at off-grid communities in emerging markets, particularly in Africa and the United Kingdom. Founded in 2012 and headquartered in Cambridge, the company addresses the energy access challenge faced by approximately 1.3 billion people globally. Azuri offers a range of innovative solar solutions, including AzuriTV, a solar-powered television; the Indigo pay-as-you-go system, which enables solar electricity delivery through scratch card payments; the Azuri Quad solar home system, which provides LED lighting, mobile phone charging, and other household needs; and the PayGo system, delivering clean energy to rural households without electricity. With an extensive distribution network across Kenya, Uganda, South Sudan, Zambia, South Africa, and other countries, Azuri leverages mobile technology to transform energy access into an affordable service, allowing users to pay for solar power similarly to how they pay for mobile phone services, thereby reducing reliance on costly kerosene.

IBEX Innovations Limited, established in 2010 and based in Sedgefield, UK, specializes in developing and commercializing advanced X-ray detector technology. The company's flagship product, IBEX multi absorption plate (MAP) technology, enhances standard X-ray detectors to generate high-sensitivity materials information while retaining key characteristics such as speed, signal-to-noise ratio, spatial resolution, and imaging area. IBEX Innovations serves diverse applications including bone mineral density measurement in medical diagnostics, electronics inspection, food safety, and security screening. The company collaborates with academic institutions like Durham University for technology development and NHS trusts for medical application validation. Backed by venture capital funding from Northstar Ventures, IP Group, Nordson Incorporated, Innovate UK, and the European Commission, IBEX Innovations aims to revolutionize X-ray imaging across various industries.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Aqdot Limited is a company based in Cambridge, United Kingdom, that specializes in the manufacture of smart microcapsules through innovative fabrication technology. Founded in 2012, Aqdot's approach utilizes a one-step shrink-wrap method, integrating emulsion technology and supramolecular chemistry, to simplify the microencapsulation process. This technology is designed to create customizable microcapsules that serve various industries, including home care, beauty, and agrochemicals. It enables the protection and targeted release of valuable active ingredients, such as enzymes in laundry detergents and fertilizers in agriculture. Aqdot's energy-efficient production methods contribute to lower energy consumption and reduced waste, positioning the company within the multi-billion-dollar microencapsulation market, which has established applications across numerous sectors, including personal care, food, and agrochemicals.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

AccelerComm Ltd is a semiconductor IP-core company based in Southampton, United Kingdom, specializing in Forward Error Correction (FEC) and channel coding solutions for wireless communications. Founded in 2016, the company develops advanced error correction technologies, including Polar and Turbo Decoders, as well as LDPC encoding and decoding chains, which are compliant with 3GPP standards. These technologies are designed to enhance the performance of next-generation wireless communication systems, addressing challenges such as noise, interference, and poor signal quality. By offering innovative solutions that improve the efficiency and reliability of communication networks, AccelerComm aims to support the evolution of mobile technology beyond 3G and 4G standards.

C-Capture Limited is a company based in Leeds, United Kingdom, founded in 2008, specializing in the development and design of solvent systems for the removal of carbon dioxide (CO2) from gas streams. The firm employs a bottom-up approach to create proprietary carbon capture solvent technology that targets the economic and non-toxic extraction of CO2 from emission sources. This technology is particularly aimed at post-combustion capture processes in power generation and hard-to-abate industries, addressing the significant role of CO2 as a greenhouse gas and its contribution to global warming. By providing absorbents and solvents, C-Capture supports the implementation of carbon capture and storage (CCS), promoting environmentally sustainable electricity generation.

Istesso is a biotechnology company focused on drug discovery and development in the field of immunometabolism. Founded in 2017, the company aims to create disease-resolving therapies for chronic autoimmune and inflammatory conditions, including rheumatoid arthritis and multiple sclerosis. Istesso's pipeline consists of both pre-clinical and clinical assets that work by reprogramming metabolic processes to address these complex diseases. By specializing in immune metabolism, Istesso is dedicated to providing innovative solutions that enhance the diagnosis and treatment of serious health conditions, ultimately aiming to improve patient outcomes.

Featurespace is a leading company specializing in enterprise financial crime prevention, focusing on fraud and anti-money laundering solutions. The company has developed innovative technologies, including Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, which are integrated into its ARIC platform. This real-time machine learning software assesses risk and monitors customer data across more than 180 countries, allowing financial institutions to detect suspicious activities and mitigate fraud in real-time. The ARIC Risk Hub employs advanced anomaly detection techniques to help organizations identify and respond to emerging fraud threats while ensuring legitimate customer transactions are not hindered. With over 30 major global financial institutions utilizing its platform, Featurespace aims to enhance fraud management, improve customer satisfaction, and drive revenue growth for its clients.

AudioScenic Limited, founded in 2017 and headquartered in Southampton, United Kingdom, specializes in developing innovative 3D audio technology that enhances the listening experience across various industries including cinema, gaming, production, automotive, and public displays. The company utilizes small arrays of speakers combined with advanced head-tracking technologies to create controlled and independent sound beams directed to each ear, effectively simulating a virtual headphone experience without the need for traditional headphones or extensive speaker setups. This approach delivers a more authentic and immersive audio experience, allowing sounds to be perceived in three-dimensional space with remarkable clarity. AudioScenic’s technology eliminates the limitations of conventional loudspeaker systems by providing optimized sound delivery that adapitates to the listener's position. Their proprietary Virtua 3D Engine enables wide-ranging applications and cost-effective implementations, offering detailed acoustic design support to partners and customers in various market segments.

Import.io Ltd, established in 2012, is a London-based Software as a Service (SaaS) company with an additional office in Los Gatos, California. It specializes in converting unstructured web data into structured, machine-readable formats. Import.io offers a suite of products, including automated web extraction, data monitoring, visualization, and analysis tools, as well as APIs for system integration. The company also provides solutions for competitor price monitoring, MAP compliance, product matching, and customer sentiment analysis. Import.io serves over 850 customers, delivering high-quality data from millions of web sources to fuel business insights and competitive advantage.

WaveOptics, Ltd. is a designer and manufacturer of advanced augmented reality display technology, specializing in diffractive waveguides for wearable devices. Founded in 2014 and headquartered in Abingdon-on-Thames, United Kingdom, the company focuses on providing key optical components for augmented reality applications. WaveOptics employs patented technology that utilizes waveguide holography and photonic crystals to create lightweight, high-performance displays. Their innovative designs feature a high field of view and full RGB color, allowing for an enriched user experience without the bulk typically associated with traditional augmented reality systems. The company has established strategic partnerships with leading firms such as Compal, Wistron, and Plessey to enhance its product offerings and market reach.